# Ofloxacin plus rifampicin versus doxycycline plus rifampicin in the treatment of brucellosis: a randomised clinical trial

Submission date	<b>Recruitment status</b> No longer recruiting	Prospectively registered		
04/06/2004		☐ Protocol		
Registration date	Overall study status	Statistical analysis plan		
08/06/2004	Completed	[X] Results		
Last Edited	Condition category	Individual participant data		
10/08/2007	Infections and Infestations			

### Plain English summary of protocol

Not provided at time of registration

# Contact information

#### Type(s)

Scientific

#### Contact name

Dr Oguz Karabay

#### Contact details

Izzet Baysal Faculty of Medicine Infectious Diseases and Clinical Microbiology Bolu Türkiye 14280

# Additional identifiers

**Protocol serial number** N/A

# Study information

Scientific Title

Study objectives

The aim of the present study was to investigate the efficacy, adverse effect and cost of ofloxacin plus rifampicin therapy, and doxycycline plus rifampicin therapy and evaluate in the treatment of brucellosis.

#### Ethics approval required

Old ethics approval format

#### Ethics approval(s)

Not provided at time of registration

#### Study design

Randomised controlled trial

#### Primary study design

Interventional

#### Study type(s)

Treatment

#### Health condition(s) or problem(s) studied

Brucellosis

#### Interventions

This study was carried out in the Social Security Duzce Hospital and Abant Izzet Baysal Universty Duzce Medical School in Turkey. After obtaining informed consent, a detailed medical history was taken from each patient and a complete physical examination was performed.

Patients who met the criteria for entry were randomly assigned to receive in a 1:1 ratio doxycycline plus rifampicin or ofloxacin plus rifampicin:

- 1. The doxycycline plus rifampicin group had 14 patients who received doxycycline 100 mg twice daily and rifampicin 600 mg once daily for 45 days
- 2. The ofloxacin plus rifampicin group had 15 patients who received ofloxacin 400 mg once daily and rifampicin 600 mg once daily for 30 days

Patients were hospitalised for at least 10 days at the beginning of treatment in order to monitor clinical response and potential side effects. The patients were assessed and laboratory tests were also performed during the therapy period in the 2nd, 4th, and 6th week of therapy. At the end of therapy, laboratory tests were reassessed at months 1, 2 and 3, as well as whenever clinical symptoms reappeared.

#### Intervention Type

Drug

#### Phase

**Not Specified** 

#### Drug/device/biological/vaccine name(s)

Ofloxacin, rifampicin, doxycycline

#### Primary outcome(s)

Not provided at time of registration

#### Key secondary outcome(s))

Not provided at time of registration

#### Completion date

01/12/2001

# Eligibility

#### Key inclusion criteria

Patients suspected to have brucella infection on the basis of clinical (fever, limb and back pains, sweating, fatigue, hepatomegaly, splenomegaly, arthritis, sacroileitis, spondylitis, orchitis and headache) and laboratory findings were hospitalised. The diagnosis was based on the presence of signs and symptoms compatible with brucellosis including a positive agglutination titre (greater than or equal to 1/160) and/or a positive culture. All sera obtained from the patients were examined by serial dilution (from 1:10 to 1:1280) using bacterial antigen.

#### Participant type(s)

**Patient** 

#### Healthy volunteers allowed

No

#### Age group

**Not Specified** 

#### Sex

**Not Specified** 

#### Key exclusion criteria

Not provided at time of registration

#### Date of first enrolment

01/12/1999

#### Date of final enrolment

01/12/2001

## Locations

#### Countries of recruitment

Türkiye

#### Study participating centre Izzet Baysal Faculty of Medicine

Bolu Türkiye 14280

# Sponsor information

#### Organisation

Izzet Baysal Faculty of Medicine (Turkey)

#### **ROR**

https://ror.org/01x1kqx83

# Funder(s)

## Funder type

Not defined

#### Funder Name

Not provided at time of registration

# **Results and Publications**

Individual participant data (IPD) sharing plan

# IPD sharing plan summary

Not provided at time of registration

#### **Study outputs**

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	Results	23/06/2004		Yes	No